The COVID-19 vaccine developed by Guangzhou nBiomed Co Ltd will enter the first phase of clinical trials, which will be conducted by the National Clinical Research Center for Respiratory Disease in Guangzhou.
Located in Huangpu district, Guangzhou nBiomed completed the design of the first-generation vaccine for COVID-19 on Jan 24, and the selection of the Ad5 adenovirus vector-based candidate vaccine strain in the following 25 days. The vaccine was proved effective in mice on Feb 18 and macaques on Feb 21.
The enterprise filed the patent application to the National Intellectual Property Administration in late February and obtained authorization for China's first COVID-19 vaccine using adenovirus vectors on July 10. It signed a cooperation agreement with Hualan Biological Bacterin Co Ltd on Aug 18, which is expected produce more than 100 million vaccines annually.
A cooperation agreement is signed between Guangzhou nBiomed and Hualan Biological Bacterin on Aug 18.
Currently, Guangzhou nBiomed is committed to the development of a second-generation vaccine, which will use a different adenovirus vector from Ad5.